Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego

Yahoo Finance07:28 ET

Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?

Yahoo FinanceJul 1 20:40 ET

Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral

Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral

Dow JonesJun 28 08:06 ET

Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating

Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average

Moomoo NewsJun 28 06:31 ET · Ratings

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."

Yahoo FinanceJun 27 08:00 ET

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

Yahoo FinanceJun 26 18:00 ET